Drug Company R&D Spending Rises
WASHINGTON--A survey of an industry trade group finds that US research-based pharmaceutical companies plan to spend $20.6 billion for research and development in 1998, an amount equal to 19.6% of the industry’s projected annual revenues. This represents an increase of 10.7% over last year’s R&D funding by the companies, according to the Pharmaceutical Research and Manufacturers of America (PhRMA).
WASHINGTON--A survey of an industry trade group finds that US research-based pharmaceutical companies plan to spend $20.6 billion for research and development in 1998, an amount equal to 19.6% of the industrys projected annual revenues. This represents an increase of 10.7% over last years R&D funding by the companies, according to the Pharmaceutical Research and Manufacturers of America (PhRMA).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
